EPZM Prices Offering At $20.75/Share

(RTTNews) - Epizyme Inc. (EPZM) has offered to sell 6 million shares of its common stock to the public at a price of $20.75 each. The underwriters have a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discount.

The offering is expected to close on or about March 23, 2015, subject to customary closing conditions.

Epizyme ended 2014 with cash of $190.1 million.

The company has a number of milestones related to its two lead programs, EPZ-5676 and EPZ-6438, to watch out for in the coming months.

The updated data from a phase I dose escalation study of EPZ-6438 in patients with B-cell lymphomas or advanced solid tumors are to be disclosed at a medical meeting in mid-2015 while data from the first two arms of a phase II study of EPZ-6438 in non-Hodgkin lymphoma are anticipated in mid-2016.

The company expects data from a phase I study of EPZ-5676 in the 54 mg/m2 expansion cohort in adult acute leukemia patients to be disclosed before the end of 2015. Enrollment in a phase I study of EPZ-5676 in pediatric acute leukemia patients is slated for completion in the second half of 2015.

EPZM closed Tuesday's trading at $21.13, down 4.26%.